These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 32996020)
1. Clinicopathological Features and Outcomes in Individuals with Breast Cancer and ATM, CHEK2, or PALB2 Mutations. Bergstrom C; Pence C; Berg J; Partain N; Sadeghi N; Mauer C; Pirzadeh-Miller S; Gao A; Li H; Unni N; Syed S Ann Surg Oncol; 2021 Jun; 28(6):3383-3393. PubMed ID: 32996020 [TBL] [Abstract][Full Text] [Related]
2. Diagnosis, Management, and Surveillance for Patients With PALB2, CHEK2, and ATM Gene Mutations. Fencer MG; Krupa KA; Bleich GC; Grumet S; Eladoumikdachi FG; Kumar S; Kowzun MJ; Potdevin LB Clin Breast Cancer; 2023 Jun; 23(4):e194-e199. PubMed ID: 36966080 [TBL] [Abstract][Full Text] [Related]
3. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Cragun D; Weidner A; Tezak A; Clouse K; Pal T Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176 [TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes. Singh K; Scalia J; Legare R; Quddus MR; Sung CJ Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781 [TBL] [Abstract][Full Text] [Related]
5. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626 [TBL] [Abstract][Full Text] [Related]
7. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243 [TBL] [Abstract][Full Text] [Related]
8. Rare, protein-truncating variants in Decker B; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Ahmed S; Baynes C; Conroy DM; Brown J; Luben R; Ostrander EA; Pharoah PD; Dunning AM; Easton DF J Med Genet; 2017 Nov; 54(11):732-741. PubMed ID: 28779002 [TBL] [Abstract][Full Text] [Related]
9. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350 [TBL] [Abstract][Full Text] [Related]
10. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer. Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279 [TBL] [Abstract][Full Text] [Related]
11. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis. Lowry KP; Geuzinge HA; Stout NK; Alagoz O; Hampton J; Kerlikowske K; de Koning HJ; Miglioretti DL; van Ravesteyn NT; Schechter C; Sprague BL; Tosteson ANA; Trentham-Dietz A; Weaver D; Yaffe MJ; Yeh JM; Couch FJ; Hu C; Kraft P; Polley EC; Mandelblatt JS; Kurian AW; Robson ME; JAMA Oncol; 2022 Apr; 8(4):587-596. PubMed ID: 35175286 [TBL] [Abstract][Full Text] [Related]
12. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310 [TBL] [Abstract][Full Text] [Related]
13. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
14. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005 [TBL] [Abstract][Full Text] [Related]
15. Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes. Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Katz SJ JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426465 [TBL] [Abstract][Full Text] [Related]
16. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2. Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers. Toss A; Tenedini E; Piombino C; Venturelli M; Marchi I; Gasparini E; Barbieri E; Razzaboni E; Domati F; Caggia F; Grandi G; Combi F; Tazzioli G; Dominici M; Tagliafico E; Cortesi L Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33919281 [TBL] [Abstract][Full Text] [Related]
18. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample. Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217 [TBL] [Abstract][Full Text] [Related]
19. The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024). Kleiblová P; Novotný J; Cibula D; Curtisová V; Dubová O; Foretová L; Germanová A; Janatová M; Havránek O; Hojsáková M; Hudcová M; Koudová M; Krutílková V; Palacova M; Paulich S; Petrakova K; Presl J; Puchmajerová A; Soukupová J; Šenkeříková M; Šimková Z; Štěpánková H; Šubrt I; Tachecí I; Tesner P; Urban O; Veselá K; Vilímová Š; Vlčková Z; Vočka M; Weinberger V; Zikán M; Zimovjanová M; Kleibl Z Klin Onkol; 2024; 38(4):292-299. PubMed ID: 39174333 [TBL] [Abstract][Full Text] [Related]
20. Profiling of the genetic features of patients with breast, ovarian, colorectal and extracolonic cancers: Association to CHEK2 and PALB2 germline mutations. Infante M; Arranz-Ledo M; Lastra E; Olaverri A; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M Clin Chim Acta; 2024 Jan; 552():117695. PubMed ID: 38061684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]